Clearmind Medicine signs LOI to acquire 51% stake in EV wireless charging firm

Clearmind Medicine Inc. (Nasdaq: CMND) announced on August 3, 2026 that it entered into a non-binding Letter of Intent to acquire a 51% stake in a company described as a leading intelligent EV wireless charging solutions provider for automated parking systems and autonomous mobile platforms.¹

The target company develops intelligent wireless charging solutions for automated parking systems and autonomous mobile platforms.¹ Its technology relies on smart communication and dynamic energy management to deliver continuous charging output up to 10 kilowatts, and according to the release the system requires no cables, no manual connections, or traditional charging infrastructure.¹ The release also states that the system integrates seamlessly with robotic parking systems while enabling real-time energy management.¹

Under the terms disclosed, Clearmind will acquire the majority stake for an aggregate purchase price of $2.5 million.¹ As a condition tied to closing, the company will extend a loan to the acquired company in the principal amount of $1.5 million.¹ That loan will bear interest at 4% per annum and is to be repaid two years after closing.¹

The deal has not closed.¹ Per the filing, finalizing the acquisition still requires signed definitive agreements, completion of due diligence, and clearance of unspecified closing conditions .

Clearmind separately describes itself as a clinical-stage biotech working on non-hallucinogenic, "second generation" neuroplastogen-derived therapeutics, with a stated focus that includes alcohol use disorder . The company reports an intellectual property portfolio of nineteen patent families, including 32 granted patents.¹ The filing was signed by CEO Adi Zuloff-Shani .¹